Carrie S. Oliphant, PharmD, BCPS

<div id="article-content-body"> <p>Amiodarone, a class III antiarrhythmic, has become the drug of choice for the management of supraventricular and ventricular...

<div id="article-content-body"> <p>Amiodarone, a class III antiarrhythmic, has become the drug of choice for the management of supraventricular and ventricular...

<div id="article-content-body"> <p>Amiodarone, a class III antiarrhythmic, has become the drug of choice for the management of supraventricular and ventricular...

This review will highlight clinically significant drug interactions amongst the NOACs—dabigatran, rivaroxaban, and apixaban—to provide strategies for managing these interactions.

This review will highlight clinically significant drug interactions amongst the NOACs—dabigatran, rivaroxaban, and apixaban—to provide strategies for managing these interactions.

This review will highlight clinically significant drug interactions amongst the NOACs—dabigatran, rivaroxaban, and apixaban—to provide strategies for managing these interactions.

The purpose of this brief summary is to focus attention on amiodarone-induced lung disease so that clinicians will be vigilant in monitoring for this serious and potentially fatal adverse drug reaction. ...

The purpose of this brief summary is to focus attention on amiodarone-induced lung disease so that clinicians will be vigilant in monitoring for this serious and potentially fatal adverse drug reaction. ...

The purpose of this brief summary is to focus attention on amiodarone-induced lung disease so that clinicians will be vigilant in monitoring for this serious and potentially fatal adverse drug reaction. ...